Evox Therapeutics Receives up to €800M from Takeda To Tackle Rare Diseases

The Japanese pharmaceutical company Takeda has struck a deal worth up to €803M with UK biotech Evox Therapeutics to develop rare disease treatments delivered to cells via nanocapsules called exosomes. As part of the deal,...

Sanofi Expands COVID-19 Pipeline with Translate Bio Partnership

Translate Bio CEO Ronald C. Renaud Jr. Sanofi Pasteur will partner with Translate Bio to develop an mRNA vaccine for preventing COVID-19, the companies said today, through a partnership that builds on a nearly two-year-old...

This Startup is Making a Cancer Vaccine out of Viruses

Valo Therapeutics is operating both in the UK and Finland to develop a cancer vaccine based on a virus designed to kill tumors. Mission: To combine two different immunotherapy techniques — oncolytic viruses and cancer...

Mining the SARS-CoV-2 Genome for Answers

Thirty thousand base pairs make up the (relatively tiny) SARS-CoV-2 genome. A singular genome holds limited information. But, by comparing multiple genomes from different patients, animals, places, or time periods, the DNA’s information can...

Immune System Weakened by High Dietary Salt

The results of studies in mice and in humans suggest that a high-salt diet (HSD) may weaken some parts of the immune system. A research team headed by scientists at the University Hospital Bonn,...

Maintaining VDR levels in pancreatic cells could protect against diabetes

Maintaining vitamin D receptor (VDR) levels in pancreatic cells that synthesize and secrete insulin (β cells) could contribute to protecting against the development of diabetes and counteract pancreatic cell damage caused by the progression...

Study suggests potential therapeutic strategy against diabetes

Reviewed by Emily Henderson, B.Sc.Mar 26 2020 Maintaining vitamin D receptor (VDR) levels in pancreatic cells that synthesize and secrete insulin (β cells) could contribute to protecting against the development of diabetes and counteract pancreatic...

FDA approves immune-modulating therapy for treatment of multiple sclerosis

Reviewed by Emily Henderson, B.Sc.Mar 26 2020 The U.S. Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research, for the treatment of adults with relapsing forms of multiple sclerosis. The...

Kids & COVID-19 website provides resources for pediatric healthcare providers and families

Credit: University of Maryland School of Medicine, Joanne Morrison BALTIMORE, MD, March 26 – The University of Maryland School of Medicine has launched a special COVID-19 website...

Silence Therapeutics to Work With AstraZeneca in RNAi Deal Worth up to €1.8B

AstraZeneca is recruiting RNAi specialist Silence Therapeutics to develop treatments for cardiovascular, renal, metabolic, and respiratory diseases.  RNA interference, or RNAi, is a relatively new field of medicine in which therapeutic small interfering (si)RNA molecules...